PD-L1 on CTCs enables monitoring, recurrence tracking, and minimal residual disease. Publications 3 June 2025 Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients. High prevalence of PD-L1–positive circulating tumor cells in colorectal cancer highlights their role in minimal residual disease and recurrence monitoring. Background The role of circulating tumor cells (CTCs) has been well established in predicting survival in metastatic settings, particularly in breast, colorectal, and prostate cancers. However, their clinical utility has been limited due to high costs, variability in sensitivity and accuracy, and the use of cutoff-based interpretations. The biological significance of CTCs—from extravasation and invasion to their contribution to tumor microenvironment dynamics and tumor burden—suggests greater clinical relevance than is currently applied in practice. Their role in monitoring minimal cellular residual disease (MCRD), especially in early-stage cancers post-surgery, remains underexplored, including decisions regarding therapy duration in diseases such as colorectal cancer and longitudinal monitoring for recurrence. Dynamic PD-L1 expression on CTCs may indicate incomplete tumor resection or treatment response and may also reflect cellular dormancy in circulation, potentially enabling immune evasion. In this study, we report the expression of PD-L1 on CTCs and CTC clusters in colorectal cancer patients. Methods We retrospectively analyzed 666 colorectal cancer patients (63.06% male and 36.94% female), spanning early- to late-stage disease, for the presence of CTCs with and without PD-L1 expression, as well as CTC clusters. CTCs were detected using the CDSCO-approved OncoDiscover platform in 1.5 mL of peripheral blood. Cells were classified as CTCs if they were EpCAM⁺, CK18⁺, DAPI⁺, and CD45⁻, and were identified using an automated Zeiss microscope system. Results At baseline analysis, 74.25% (n = 591) of patients had ≥1 CTC per 1.5 mL of blood. CTC counts ranged from 1 to 20 cells. Among patients with detectable CTCs, 74.62% (n = 441) exhibited PD-L1 expression. The highest proportion of CTCs (~25.86%, n = 352) was observed in the 61–70 years age group. CTC clusters were detected in 13.00% (n = 156) of patients, and notably, more clusters were observed during follow-up compared with baseline. The mean CTC count (including clusters) was 1.71, while the mean PD-L1–positive CTC count was 1.02. Conclusions PD-L1 expression on CTCs may contribute to their ability to persist in circulation through immune evasion, potentially enabling dormancy via surface protein overexpression that helps them avoid elimination by immune T cells. The CTC–PD-L1 assay shows strong potential for patient surveillance both before and after treatment in assessing minimal cellular residual disease. Further clinical studies in this direction are strongly warranted. View Publication Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Actorius and ACTREC Partner to Advance Clinical Cancer Research. Press Release 5 February 2026 Actorius and ACTREC Partner to Advance Clinical Cancer Research. A collaborative research initiative to study the practical utility of Circulating Tumor Cells and their capture and depletion from patient's blood as possible aid to adjunct therapeutics. Big step forward for Actorius Innovations and Research 🙌 Actorius recently signed an MOU with Advanced Centre for Treatment, Research and Education in Cancer(ACTREC) to collaborate on clinical studies and research spanning - practical utility of Circulating Tumor Cells and their capture and depletion from patient’s blood as possible aid to adjunct therapeutics. Slowing down or blocking metastasis cascade in early stage patients. Extremely bold and breakthrough innovation hypothesis. This partnership is about taking science closer to patients—generating meaningful real-world evidence, strengthening translational research, and asking the right clinical questions where it truly matters. The MOU was signed by Dr. Pankaj Chaturvedi , Director, ACTREC, and Dr. Jayant Khandare , Co-Founder & CSO, Actorius Innovations and Research. Excited about what lies ahead and the impact this collaboration can create together. Aravindan Vasudevan Rick Kamble Know more Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Actorius Innovations at ASCO Annual Meeting 2026 Publications 17 March 2026 ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood. Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk. Abstract Background Despite no radiological or pathological evidence of disease, about 25–50% of stage II–III colorectal cancer (CRC) and early-stage breast cancer (BC) patients are known to experience recurrence. The presence of circulating tumor cells (CTCs) with epithelial–mesenchymal transition (EMT) traits represents aggressive systemic disease. Through autonomous oncogenic activation, epithelial cells acquire invasive properties that enable metastasis. A high EMT score combined with immune checkpoint expression, such as PD-L1, may allow tumor cells to evade immune surveillance. Following curative-intent surgery and therapy, CTCs represent minimal cellular residual disease (MCRD) and serve as strong predictors of recurrence. In this study, we present an automated extracorporeal device designed to capture, analyze, and deplete CTCs for further clinical evaluation. Methods We retrospectively analyzed 66 patients, including stage II–III CRC patients (n = 41) and breast cancer patients (n = 25). Whole blood samples were processed to deplete CTCs using the OncoMetastat device. Among the CRC patients, 12 were female and 29 were male. The average age of BC and CRC patients was 53.6 and 58 years, respectively. The device consists of a spiral channel (127 × 85 × 5 mm; spiral span: 66 mm; width: 4 mm) 3D-printed using biocompatible resin and filled with anti-EpCAM antibody–conjugated glass beads (GB). The system includes a controller and a peristaltic pump that circulates blood in and out of the spiral channels. Vibrational energy induces motion in the glass beads to enhance cell capture. Hemolysis, protein binding, leukocyte adsorption, and CTC capture efficiency were evaluated. CTC capture efficiency was compared with the CDSCO-approved OncoDiscover CTC technology in India. Blood samples were pumped into the device and incubated with affinity-enriched glass beads for 30 minutes under constant vibration (200 Hz) to enhance CTC capture and prevent blood stagnation. CTCs were confirmed using CK18⁺, DAPI⁺, and CD45⁻ markers and analyzed using an automated fluorescence microscope. Results A total of 48 CTCs were detected in 58% (38/66) of patients. CTC positivity was slightly higher in breast cancer patients (60.0%) compared with CRC patients (56.1%). The mean CTC distribution was 0.73 overall, with CRC and BC both showing mean values of 0.73 and 0.72, respectively. The negative predictive value (NPV) was determined to be 0.86 (86%). Automated scanning demonstrated 100% efficiency in detecting CTCs. Low leukocyte adhesion was observed with anti-EpCAM–coated glass beads. White blood cell (WBC) counts varied by cancer type, with mean counts of 4.9 × 10⁶/mL for breast cancer and 3.9 × 10⁶/mL for colorectal cancer, both lower than healthy controls (6.9 × 10⁶/mL). Clinically insignificant hemolysis (<1%) and minimal protein binding (~1.5%) were observed in the spiral channel. Glass beads subjected to vibrational energy demonstrated enhanced CTC sequestration, achieving over 90% cell capture efficiency compared with vibration-free conditions. Conclusions This study demonstrates efficient CTC depletion in 66 CRC and breast cancer patients using an automated extracorporeal device. Early-stage CRC and BC patients with detectable CTCs may have a higher risk of developing distant metastasis. Therefore, following complete remission, the use of an extracorporeal device to deplete CTCs could potentially reduce the risk of metastatic progression. View Publication Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

CTCs as biomarkers for relapse detection in rectal cancer with liver metastasis. Manuscript 29 June 2024 Manuscript: Circulating Tumor Cells as Biomarkers for Relapse Detection in Rectal Cancer with Liver Metastasis: Insights from a Case Report In this case report we demonstrate the utility of CTC as a sensitive marker to detect MRD. CTCs play a crucial role in the context of MRD in colorectal cancer, offering a valuable biomarker for prognosis, treatment monitoring, and early detection of recurrence. A 70-year-old female diagnosed case of rectal carcinoma (T3N2M0) received FOLFOX × 2 cycles followed by CAPOX × 2 cycles. She then underwent chemoradiation using capecitabine as a radiosensitiser, followed by laparoscopic tumor resection. The histopathology report showed tumour regression grade 2 (TRG2) response. Subsequently, the patient received 4 cycles of CAPOX but developed grade 2 peripheral neuropathy, leading to modification of her treatment to capecitabine alone for an additional 2 cycles. A whole-body positron emission tomography–computed tomography (PET-CT) scan at this stage showed no evidence of disease. However, a liquid biopsy test detected the presence of two circulating tumor cells (CTCs). An MRI of the abdomen and pelvis was conducted, revealing multiple live lesions (4 mm–6 mm) in segment IV/VIII of the liver, with no sign of local disease. To manage liver metastasis, the patient received 1 cycle of FOLFIRI while awaiting selective internal radiotherapy (SIRT), followed by 5 cycles of FOLFIRI. Three years later, her PET scans were observed to be completely normal. This case highlights the critical role of CTCs as a biomarker for detecting minimal residual disease (MRD) or relapse. Without CTC monitoring, the liver metastasis—which was successfully treated with SIRT—would likely have been missed under standard cancer care guidelines. As of today, the patient is completely disease-free, underscoring the importance of thorough investigation using advanced CTC liquid biopsy biomarkers in managing rectal cancer with liver metastasis. View Manuscript Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Dynamic device captures CTCs safely, enabling monitoring and metastatic control. Publications 3 June 2025 Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival. Background Primary tumors are known to shed circulating tumor cells (CTCs), promoting systemic dissemination and increasing the risk of metastasis to distant organs. Approximately 90% of cancer-related deaths are directly associated with metastasis. Several studies in animal models suggest improved overall survival following reduction in the number of CTCs in circulation. In this study, we demonstrate the capture of CTCs using a continuous blood-flow device incorporating three-dimensional glass substrates (3D GS) conjugated with affinity ligands, including anti-epithelial cell adhesion molecule (EpCAM) antibody and transferrin (Tf), in cancer patients. Methods A bi-spiral, plano-horizontal, optically transparent device fabricated from biocompatible resin with multiple channels for continuous blood flow was designed using a 3D printer. The circulation device comprised 14 loops capable of holding 17.5 mL of blood and containing 680 glass substrates (2 mm diameter) conjugated with anti-EpCAM antibody and transferrin. The system was mechanized for functional circulation using three pumps. Pyrogenicity resulting from blood passage through the device was evaluated in three New Zealand White rabbits according to ISO:10993-11 guidelines for systemic toxicity assessment. Additionally, 27 blood samples from patients with early- and late-stage cancers across nine cancer types, including colorectal, lung, breast, and ovarian cancers, were processed using the OncoDialysis assay. The cohort consisted of 48.15% male and 51.85% female patients. CTCs were captured using five glass substrates from 1.5–5 mL of blood and validated using CK18 and CD45 markers through fluorescence microscopy. Samples were also analyzed using the Drug Controller, India–approved OncoDiscover technology for comparative evaluation. Results No hemolysis was observed as a result of the device. Continuous circulation of up to 5 mL of blood successfully demonstrated CTC capture within the flow system. All rabbits remained healthy during testing, and none exhibited an individual temperature increase of 0.5°C or more compared with controls, indicating no systemic toxicity. The OncoDialysis assay detected CTCs in 48.15% of patients (n = 13/27), yielding a total of 14 CTCs (12 single CTCs and 2 clusters), with a mean CTC distribution of 0.51 per 1–5 mL of blood. The OncoDiscover platform isolated 23 CTCs (18 single CTCs and 5 clusters), with a mean CTC distribution of 0.8. A concurrence rate of 74.07% was observed between the two platforms. In 40.74% of cases (n = 11/27), CTCs were detected by both systems. Conclusions We developed a dynamic in vitro blood circulation device with demonstrated safety in animal studies, capable of selectively capturing circulating tumor cells from patient blood. Reduction of CTC burden may hold significant therapeutic potential in limiting metastatic spread and improving overall survival in epithelial-origin cancers, both in treated and untreated settings. View Publication Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Discover the Actorius Research Centre, where scientists advance cancer diagnostics, liquid biopsy technologies, and innovative oncology solutions. Research Centre We are in pursuit of identifying and developing life-saving solutions for global healthcare problems with a focus on cancer diagnostics and cure. A diagnostic test that is patented globally and approved by DCG(I) Know more Requires just 10ml of blood The OncoDiscover® CTC Test requires only 5ml of the patient’s blood sample. Can be done frequently The OncoDiscover® CTC Test can be done at regular intervals for continuous monitoring and arriving at therapy decisions. No exposure to radiation The test is conducted on patient’s blood sample at our diagnostic laboratory. Patients don’t have to go through any physically painful and emotionally stressful tests that use radiations. Convenient. No fasting. Our registered phlebotomists can collect the blood samples from patient’s home. There are no restrictions with regards to fasting or medication for the blood sample. Our story so far An innovation-driven organisation 11000+ Patients Served 100+ Scientists 100+ Publications 1000+ Patients Served Know more Mission, Vision & Purpose Innovating with Intent Our mission, vision, and purpose reflect our commitment to meaningful progress and measurable outcomes. Mission To develop innovative methodologies to develop diagnostic tests that provide early indicators of oncogenesis and enable informed treatment strategies. Vision To collectively advance and improve human health by developing biomedical innovations into practical applications that have wider reach, accessibility and affordability. Purpose To positively impact everyone, by developing solutions that have reduced time to decision making and providing precise information for a chosen course of action. Our Values What We Stand For Our values define our commitment to rigorous science, responsibility, and meaningful impact. Work on challenges with cutting-edge science and innovation. Work towards making it accessible and affordable to the masses. Ensure critical clinical validations for every outcome. Bio-materials with high specificity, efficiency and sensitivity. Scientific disciplines with interdisciplinary intelligence at the core. Take every little step to ensure cancer patient’s lives are saved. Detect cancer relapse early, when it can be cured. We are committed to bringing stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. Focused on creating novel cancer diagnostic tests. Know more Rigour in every action. Every product undergoes intense design and development. Leaving no stone unturned. We follow the most stringent quality norms like ISO13485 and regulatory requirements. Passionate and emphatic. We are committed to developing solutions for unmet medical needs. We build high-risk innovative products, which have a very long life-cycle, using novel biomaterials. With collaboration with knowledge leaders Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Actorius Innovations at AACR 2026 Publications 17 March 2026 AACR 2026: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion. Abstract Background Prostate cancer (PC) detection remains challenging due to the limited specificity and sensitivity of current screening methods, including PSA testing. PSA testing does not reliably distinguish aggressive disease from indolent forms, often leading to overdiagnosis and overtreatment. Circulating tumor cells (CTCs), however, offer greater clinical value by providing real-time insights into tumor biology, disease progression, and treatment response. Unlike PSA, CTCs represent a dynamic biomarker reflecting systemic minimal cellular residual disease (MCRD), which can support monitoring and guide personalized prostate cancer management. In addition, the overexpression of PD-L1 on CTCs provides insight into immune evasion mechanisms and may have predictive and prognostic value in prostate cancer. In this study, we report the capture of CTCs, including PD-L1–positive cells and CTC clusters, in prostate cancer patients. Methods A retrospective analysis was conducted on 239 prostate cancer patients to evaluate the presence of PD-L1–positive CTCs and CTC clusters. The cohort included 216 (90.4%) baseline samples and 23 (9.6%) follow-up samples. CTCs were isolated using the CDSCO-approved OncoDiscover Test (India), which employs anti-EpCAM antibody–based immunomagnetic enrichment from 1.5 mL of blood. CTCs were identified as CK18⁺/DAPI⁺/CD45⁻ cells with PD-L1 expression and distinct morphology. Automated fluorescence imaging was used to quantify signal intensities and correlate them with clinicopathological parameters. Patients were stratified by age, and quantitative analyses of CTC positivity, PD-L1 expression, and CTC cluster frequency were performed. Results CTCs were detected in 173 patients (72.4%), while 66 patients (27.6%) were CTC-negative. Among 157 evaluable samples for PD-L1 expression, 131 (54.8%) were PD-L1 positive and 26 (10.9%) were negative. CTC clusters were observed in 19 patients (11%), while 154 patients (89%) exhibited only single CTCs. At baseline, CTCs were detectable in 70.4% of patients, increasing to 91.3% in follow-up samples. PD-L1–positive CTCs were observed in 52.3% of patients at baseline and 85.7% at follow-up. Additionally, PD-L1–positive CTC clusters increased from 10.5% at baseline to 13.1% at follow-up. The predominant age groups were 61–70 years (39.0%) and 71–80 years (39.9%), together comprising nearly 80% of the cohort. The mean distribution of CTC counts per patient was 1.14 for total CTCs, 0.95 for PD-L1–positive CTCs, and 0.12 for CTC clusters. Conclusion A high prevalence of CTCs and PD-L1 expression was observed among prostate cancer patients, particularly in older age groups. The detection of PD-L1–positive CTCs highlights the presence of confirmatory MCRD and circulating disease. Although the incidence of CTC clusters was relatively low, their presence may indicate more aggressive disease phenotypes. View Publication Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Actorius Innovations at ASCO Annual Meeting 2026 Publications 17 March 2026 ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. Abstract Background Tumor thrombus (TT) refers to the direct extension of tumor cells into a blood vessel and is often detected incidentally. It is commonly observed in renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and Wilms tumor. The presence of TT significantly worsens prognosis and alters disease staging. TT is frequently located in vessels such as the renal vein, inferior vena cava, and portal vein, requiring multidisciplinary evaluation due to its aggressive nature and risk of obstruction or embolization. Diagnostic differentiation between tumor thrombus and a “bland” thrombus (blood clot) typically relies on imaging techniques such as CT or MRI. In this study, we evaluated the association and potential role of circulating tumor cells (CTCs) expressing immune-relevant markers, such as PD-L1, in patients with tumor thrombus. The presence of CTCs originating from TT margins may help refine risk stratification and therapeutic decision-making. Methods In this observational study, 12 patients aged 51–80 years with confirmed tumor thrombus were analyzed. The cohort included patients with hepatocellular carcinoma (HCC, n = 4), pancreatic cancer (n = 3), liver cancer (n = 3), renal cell carcinoma (RCC, n = 1), and gallbladder cancer (GB, n = 1). Blood samples were analyzed for the presence of CTCs with PD-L1 expression at baseline, and three patients also had follow-up samples. Samples were processed using the CDSCO-approved OncoDiscover CTC enrichment technology. CTCs were identified using an automated Zeiss microscope based on EpCAM⁺, CK18⁺, DAPI⁺, CD45⁻, and PD-L1⁺ markers. Results A total of 16 CTCs were detected in 10 patients (83.33%) from 1.5 mL blood samples, with counts ranging from 1 to 6 CTCs per patient. At baseline, patients with HCC, pancreatic, RCC, gallbladder, and other cancers showed the presence of PD-L1–expressing CTCs. Follow-up samples revealed persistent CTC positivity, although the number of PD-L1–positive CTCs decreased. The mean CTC distribution was 1.33 for CK18-expressing CTCs. PD-L1–positive CTCs were detected in a substantial subset, with a mean distribution of 0.67 (9 CTCs among 12 patients), indicating immune-evasive potential. CTC clusters were rare and detected in only one HCC patient but persisted during follow-up. Both male and female patients demonstrated comparable CTC positivity. Conclusion The presence of CTCs in peripheral blood highlights active tumor cell dissemination from tumor thrombus margins. Although CTC clusters were infrequent, their occurrence may indicate an increased metastatic risk. This study demonstrates, for the first time, the presence of CTCs originating from tumor thrombus margins entering systemic circulation. Further studies are required to better understand their clinical implications. View Publication Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test